Crossmark

Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance

Crossref DOI link: https://doi.org/10.1186/s40164-020-00183-1

Published Online: 2020-09-26

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Klümper, Theresa

Bruckmueller, Henrike

Diewock, Tobias

Kaehler, Meike

Haenisch, Sierk

Pott, Christiane

Bruhn, Oliver

Cascorbi, Ingolf https://orcid.org/0000-0002-2182-9534
Funding

Funding for this research was provided by:

Medical Faculty, University of Kiel, Germany

Projekt DEAL
License Information

Text and Data Mining valid from 2020-09-26

Version of Record valid from 2020-09-26
More Information

Article History

Received: 30 July 2020

Accepted: 21 September 2020

First Online: 26 September 2020

Ethics approval and consent to participate

: The study was conducted according to the guidelines of Helsinki and was approved by the Ethics Committee of the Medical Faculty of Kiel University, Germany (reference number: D 426/03). Each patient gave his written informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below